Radiochemistry: A Hot Field with Opportunities for Cool Chemistry

Overview

Journal ACS Cent Sci

Specialty Chemistry

Date 2024 Jan 1

PMID 38161375

Authors

Gregory D Bowden

Peter J H Scott

Eszter Boros

Affiliations

Soon will be listed here.

Abstract

Recent Food and Drug Administration (FDA) approval of diagnostic and therapeutic radiopharmaceuticals and concurrent miniaturization of particle accelerators leading to improved access has fueled interest in the development of chemical transformations suitable for short-lived radioactive isotopes on the tracer scale. This recent renaissance of radiochemistry is paired with new opportunities to study fundamental chemical behavior and reactivity of elements to improve their production, separation, and incorporation into bioactive molecules to generate new radiopharmaceuticals. This outlook outlines pertinent challenges in the field of radiochemistry and indicates areas of opportunity for chemical discovery and development, including those of clinically established (C-11, F-18) and experimental radionuclides in preclinical development across the periodic table.

Citing Articles

(SiFA)SeFe: A Hydrophilic Silicon-Based Fluoride Acceptor Enabling Versatile Peptidic Radiohybrid Tracers.

Deiser S, Fenzl S, Konig V, Drexler M, Smith L, George M J Med Chem. 2024; 67(16):14077-14094.

PMID: 39115131 PMC: 11345769. DOI: 10.1021/acs.jmedchem.4c00924.

Improving the In Vivo Stability of [Mn]Mn(II) Complexes with 18-Membered Macrocyclic Chelators for PET Imaging.

Harriswangler C, Omweri J, Saini S, Valencia L, Esteban-Gomez D, Ranga M J Med Chem. 2024; 67(13):11242-11253.

PMID: 38935616 PMC: 11247486. DOI: 10.1021/acs.jmedchem.4c00812.

Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.

Lapi S, Scott P, Scott A, Windhorst A, Zeglis B, Abdel-Wahab M Lancet Oncol. 2024; 25(6):e236-e249.

PMID: 38821098 PMC: 11340123. DOI: 10.1016/S1470-2045(24)00030-5.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Toyohara J, Vugts D, Kiss O, Todde S, Li X, Liu Z EJNMMI Radiopharm Chem. 2024; 9(1):42.

PMID: 38753262 PMC: 11098975. DOI: 10.1186/s41181-024-00268-w.

References

Calais J . FAP: The Next Billion Dollar Nuclear Theranostics Target?. J Nucl Med. 2020; 61(2):163-165. DOI: 10.2967/jnumed.119.241232. View

Pruszynski M, Loktionova N, Filosofov D, Rosch F . Post-elution processing of (44)Ti/(44)Sc generator-derived (44)Sc for clinical application. Appl Radiat Isot. 2010; 68(9):1636-41. DOI: 10.1016/j.apradiso.2010.04.003. View

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, OSullivan J . Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014; 15(7):738-46. DOI: 10.1016/S1470-2045(14)70183-4. View

Ramdahl T, Bonge-Hansen H, Ryan O, Larsen S, Herstad G, Sandberg M . An efficient chelator for complexation of thorium-227. Bioorg Med Chem Lett. 2016; 26(17):4318-21. DOI: 10.1016/j.bmcl.2016.07.034. View

Silberstein E . Radioiodine: the classic theranostic agent. Semin Nucl Med. 2012; 42(3):164-70. DOI: 10.1053/j.semnuclmed.2011.12.002. View

Chaple I, Thiele K, Thaggard G, Fernandez S, Boros E, Lapi S . Optimized methods for production and purification of Titanium-45. Appl Radiat Isot. 2020; 166:109398. DOI: 10.1016/j.apradiso.2020.109398. View

Zhou D, Chu W, Voller T, Katzenellenbogen J . Copper-Mediated Nucleophilic Radiobromination of Aryl Boron Precursors: Convenient Preparation of a Radiobrominated PARP-1 Inhibitor. Tetrahedron Lett. 2018; 59(20):1963-1967. PMC: 6195330. DOI: 10.1016/j.tetlet.2018.04.024. View

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

Ferrier M, Stein B, Batista E, Berg J, Birnbaum E, Engle J . Synthesis and Characterization of the Actinium Aquo Ion. ACS Cent Sci. 2017; 3(3):176-185. PMC: 5364452. DOI: 10.1021/acscentsci.6b00356. View

10.

McGuinness S, Wilkinson J, Peaslee G . Heavy-ion production of Br and Br. Sci Rep. 2021; 11(1):15749. PMC: 8333326. DOI: 10.1038/s41598-021-94922-x. View

11.

Deng X, Rong J, Wang L, Vasdev N, Zhang L, Josephson L . Chemistry for Positron Emission Tomography: Recent Advances in C-, F-, N-, and O-Labeling Reactions. Angew Chem Int Ed Engl. 2018; 58(9):2580-2605. PMC: 6405341. DOI: 10.1002/anie.201805501. View

12.

Salih S, Elliyanti A, Alkatheeri A, AlYafei F, Almarri B, Khan H . The Role of Molecular Imaging in Personalized Medicine. J Pers Med. 2023; 13(2). PMC: 9959741. DOI: 10.3390/jpm13020369. View

13.

Barca C, Griessinger C, Faust A, Depke D, Essler M, Windhorst A . Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy. Pharmaceuticals (Basel). 2022; 15(1). PMC: 8780589. DOI: 10.3390/ph15010013. View

14.

Vickaryous W, Healey E, Berryman O, Johnson D . Synthesis and characterization of two isomeric, self-assembled arsenic-thiolate macrocycles. Inorg Chem. 2005; 44(25):9247-52. DOI: 10.1021/ic050954w. View

15.

Huang K, Xu Y, Packianathan C, Gao F, Chen C, Zhang J . Arsenic methylation by a novel ArsM As(III) S-adenosylmethionine methyltransferase that requires only two conserved cysteine residues. Mol Microbiol. 2017; 107(2):265-276. PMC: 5760297. DOI: 10.1111/mmi.13882. View

16.

Thiele N, Brown V, Kelly J, Amor-Coarasa A, Jermilova U, MacMillan S . An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. Angew Chem Int Ed Engl. 2017; 56(46):14712-14717. DOI: 10.1002/anie.201709532. View

17.

Ma L, Grant C, Gallazzi F, Watkinson L, Carmack T, Embree M . Development and biodistribution studies of As-labeled trithiol RM2 bioconjugates for prostate cancer: Comparison of [As]As-trithiol-Ser-Ser-RM2 vs. [As]As-trithiol-Glu-Ser-RM2. Nucl Med Biol. 2022; 108-109:61-69. DOI: 10.1016/j.nucmedbio.2022.03.003. View

18.

Makvandi M, Samanta M, Martorano P, Lee H, Gitto S, Patel K . Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma. Commun Biol. 2022; 5(1):1260. PMC: 9671962. DOI: 10.1038/s42003-022-04209-8. View

19.

Swindell E, Hankins P, Chen H, Miodragovic D, OHalloran T . Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes. Inorg Chem. 2013; 52(21):12292-304. PMC: 3893798. DOI: 10.1021/ic401211u. View

20.

Williams H, Robinson S, Julyan P, Zweit J, Hastings D . A comparison of PET imaging characteristics of various copper radioisotopes. Eur J Nucl Med Mol Imaging. 2005; 32(12):1473-80. DOI: 10.1007/s00259-005-1906-9. View